|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0031327,
umls-concept:C0178602,
umls-concept:C0205171,
umls-concept:C0205314,
umls-concept:C0384232,
umls-concept:C0439064,
umls-concept:C0442027,
umls-concept:C0679622,
umls-concept:C0851347,
umls-concept:C1289971,
umls-concept:C1708335
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-4-22
|
|
pubmed:abstractText |
This study evaluated the safety, pharmacokinetics and pharmacodynamics of ABT-761 [R(+)-N-[3-[5-(4-fluorophenylmethyl)-2-thienyl]-1- methyl-2-propynyl]-N-hydroxyurea], a new N-hydroxyurea analog.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
324-31
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9542476-Administration, Oral,
pubmed-meshheading:9542476-Adult,
pubmed-meshheading:9542476-Double-Blind Method,
pubmed-meshheading:9542476-Drug Administration Schedule,
pubmed-meshheading:9542476-Female,
pubmed-meshheading:9542476-Humans,
pubmed-meshheading:9542476-Hydroxyurea,
pubmed-meshheading:9542476-Lipoxygenase Inhibitors,
pubmed-meshheading:9542476-Male,
pubmed-meshheading:9542476-Reference Values
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
|
|
pubmed:affiliation |
Department of Pharmacokinetics and Biopharmaceutics, Abbott Laboratories, Abbott Park, IL 60064-3500, USA. shekman.wong@abbott.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
